Breakthrough Agreement Brings CBD Skincare
Brand to World Leading Asia Pacific Market
- Kuida CBD skincare products to be distributed through pharmacy,
beauty retail and online markets serving the Hong Kong territory, beginning Q4 2020
- The Asia Pacific Region ("APAC") is the highest value global
region for skincare, with 53% of global sales (Source:
Euromonitor)
- Agreement with DNO Group, a leading APAC distributor of global
brands to over 50,000 points of sale throughout the Asian
region
- Kuida product training, CBD category education, consumer-facing
promotion and brand activation to support distribution
- By 2024, the CBD market in China is anticipated to grow to approximately
US$15 billion, with the beauty and
wellness sector the main growth driver (Source: Arcview Market
Research and BDS Analytics)
- Khiron recently recognized by emerging global trend research
firm Technavio Research as one of the top global players in the CBD
cosmetics market, alongside L'Oreal SA and The Estée Lauder
Companies
TORONTO, Aug. 10, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announced that it has signed a
distribution deal for its KuidaTM CBD cosmeceutical
brand with DNO Group, a leading distributor for the Asia Pacific market. Kuida skin and body care
products will be distributed by DNO Group through their network of
retail and online channels in Hong
Kong, with first orders anticipated in Q4 2020. Distribution
is conditional on TSXV approval.
"With this distribution deal we establish a significant
footprint in Hong Kong for our
Kuida brand and gain access to the Asian Pacific beauty and
skincare market, the world's largest region for skincare products.
DNO Group have a large distribution network of over 50,000 points
of sales in the region, including prominent pharmacy, beauty retail
and online channels that we know from experience in other
jurisdictions are where our customers are choosing to purchase
Kuida products. Importantly, DNO Group brings valuable insight into
the Asian consumer profile, further supporting the impact of the
brand roll-out in Hong Kong,"
comments Alvaro Torres, Khiron CEO
and Director.
Hong Kong is a market that
serves both the local population of 7.2 million and serves as an
import hub for mainland China. The
Hong Kong personal care and
cosmetics market is experiencing robust growth with estimated
revenue of US$2.7 billion achieved in
2018 and continues to expand with many beauty and personal
care items considered daily necessities, as rising health awareness
and image-consciousness drives demand.
Seven Kuida SKU's will be distributed into the Hong Kong market, with first orders
anticipated in Q4 2020. This continues the Khiron strategy to
target specific, high-value global CBD skincare market
opportunities. Kuida is now available at over 350 points of sale in
Colombia, as well as the UK and
recently announced entry to Spain.
Khiron was recently recognized by Technavio Research as one of the
top global players in the CBD cosmetics market, alongside L'Oreal
SA and The Estée Lauder Companies. Technavio is a leading global
technology research and advisory company focused on emerging market
trends.
"Kuida CBD based skincare products are well suited for consumers
in Hong Kong, as well as for our
portfolio and distribution capabilities. Furthermore, the efficacy
of the products themselves is impressive. We expect a highly
positive sales development for Kuida in Hong Kong going forward," said DNO Group's
Managing Director, Ofri
Shaysh.
About DNO Group
DNO Group has been established with
the purpose of opening doors for international brands to business
opportunities in Asia. Our group initiates, promotes and
develops business activities, identifies business opportunities and
potential local partners, leveraging its extensive network and
cultural knowledge of the Asian market in order to accelerate
business.
We understand Asia, its
strengths and its challenges. In the last 15 years, the
principles of DNO Group have been heavily involved in conducting
business in APAC. By virtue of our experience, we provide deep
practical insights which enables international brands to succeed in
Asia. Further DNO Group information can be found at
https://www.dno-group.com
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the leading cannabis company in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both low and high THC medical cannabis products. The
Company has presence in Mexico,
Peru, Uruguay, Brazil, UK, Spain and Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage, and patient oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at www.khiron.ca, investors.khiron.ca and on
Instagram @khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-signs-first-kuida-distribution-deal-in-hong-kong-301109088.html
SOURCE Khiron Life Sciences Corp.